Health · Pharma & Biotech · 4 hrs ago
Surging demand for Lilly drugs pushes shares near record highs
Eli Lilly is a drugmaker whose shares are nearing record highs.
Demand for Zepbound and Mounjaro is surging amid a growing appetite for weight-loss drugs.
The two drugs are central to the news about Lilly's rising market value.
Morgan Stanley raised its price target for Eli Lilly as demand climbed.
A higher price target reflects a more positive view of the company's shares.
The surge is pushing Lilly shares near record highs.
No further developments are specified.
Morgan Stanley raised its price target for Eli Lilly.
TheStreet reported that demand for Zepbound and Mounjaro was surging.
The article headline said Lilly shares were near record highs.
The report was published on November 3, 2026.
- Who
- Eli Lilly and Morgan Stanley.
- What
- Morgan Stanley raised its price target for Lilly. The article linked the move to surging demand for Zepbound and Mounjaro.
- When
- November 3, 2026, the article's publication date.
- Where
- Not stated.
- Why
- The article said demand for Zepbound and Mounjaro was surging.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Company
- Eli Lilly
- Analyst firm
- Morgan Stanley
- Drugs
- Zepbound and Mounjaro
- Publication date
- November 3, 2026